Similarly, analysis of data from 891 NSCLC patients treated with atezolizumab revealed increased activity of B cells and plasma cells, indicating their crucial role in extending overall survival, regardless of CD8 T cell characteristics. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.